 Sativex mouth spray is used to treat the central nervous system and alleviate the symptoms of multiple sclerosis . Shares in UK biotech firm GW Pharmaceuticals lost a third of their value after UK regulators said they wanted more evidence about the drug's benefits . Canadian authorities have said the drug will be considered for approval . It will be the first time a cannabis-based drug has been approved anywhere in the world, representing a landmark for GW Pharma and for patients with MS . The latest news sent shares in GW Pharma up 8.5p, or 8.1%, to 113.5 p.A. The company expects full approval for SativeX early in 2005 . There are currently 85,000 MS sufferers in the UK and 50,000 people in Canada have been diagnosed with the condition in the U.S. Many patients already smoke cannabis to relieve their symptoms of the condition . Back to Mail Online home to Daily Mail Online Online home. Back to the page you came from: http://www.mailonline.com/newsquiz.